TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02571192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Description: single oral dose 50mg SHP626 with approximately 5.95 μCi RAD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5.95 μCi RAD
Study: NCT03875859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remetinostat
Description: Topical 1% remetinostat gel
Study: NCT02711735

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RUTI® Therapeutic vaccine
Description: Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching RUTI® Placebo
Description: Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
Study: NCT02777814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: anti hepatitis B virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: anti hepatitis B virus
Study: NCT04040023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron and vitamin Deficiencies Correction Program
Description: Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBMi: Training program to improve transfusion practices
Description: Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.

Intervention type: OTHER
Group type: OTHER
Intervention: PBMi: Training program to improve transfusion practices
Description: Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
Study: NCT05387850

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00665938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics
Study: NCT00555386

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy and Selenium
Description: 6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy and Selenium
Description: 6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
Study: NCT03547700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
Study: NCT02752906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01069809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: HIV-1 Immune Therapy
Study: NCT03484416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate 1500 Mg with Vitamin D
Description: Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
Study: NCT03884296

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist
Description: Quadrivalent, live, attenuated influenza vaccine, intranasal spray
Study: NCT04454879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
Study: NCT01308567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (XRP6976)
Description: Pharmaceutical form: Solution for injection'; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT01612312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard percutaneous coronary intervention
Description: In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
Study: NCT00387452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise and Strength Exercise
Description: 6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
Study: NCT04029909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan 0.6mg/m2/d
Description: 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8mg/m2/d
Description: 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4mg/m2/d
Description: 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
Study: NCT00280228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Skills Parent Management Parent-Adol Negotiation
Description: Acute treatment for 12 weeks followed by three monthly booster sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard outpatient treatment for behavioral problems and substance use
Study: NCT03575624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and goal-setting education, yoga
Description: This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice
Study: NCT01069809

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo Injection
Study: NCT01085773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise on Prescription
Description: The physical training consisted of both aerobic and strength training and took place in supervised groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
Study: NCT06118944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICB00 IOL
Description: Bilateral implantation of ICB00 IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZCB00 IOL
Description: Bilateral implantation of ZCB00 IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CNA0T0 IOL
Description: Bilateral implantation of CNA0T0 IOL
Study: NCT01711476

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2
Description: In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Lifestyle counseling ARM 1
Description: In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
Study: NCT01467089

Intervention type: OTHER
Intervention: Two way video assessment
Description: Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
Study: NCT04487951

Intervention type: OTHER
Intervention: Pro BNP , Vitamin D
Description: This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.

Intervention type: OTHER
Intervention: Pro BNP , Vitamin D
Description: This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
Study: NCT00711438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service (BIS)
Description: BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (Standard care)
Description: Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
Study: NCT03269227

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionation with Tomotherapy
Description: Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment.
Study: NCT00471952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxalt 10mg MLT plus Caffeine 75mg
Description: One migraine attack will be treated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxalt 10mg MLT plus Placebo
Description: One migraine attack will be treated with Maxalt 10mg plus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Placebo
Description: One migraine attack will be treated with double placebo
Study: NCT01982812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Levetiracetam
Description: liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard AED
Description: Active comparitor, Standard AED
Study: NCT02469259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04844762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes
Description: In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes
Description: In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
Study: NCT03247218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: a low-moderate affinity, uncompetitive, NMDAR antagonist
Study: NCT02524535

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic alliance
Study: NCT04844762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes
Description: In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes
Description: In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand menthol cigarettes and substitutes
Description: In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand menthol cigarettes and substitutes
Description: In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand menthol cigarettes and substitutes
Description: In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes and menthol cigarettes
Description: In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes and menthol cigarettes
Description: In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes and menthol cigarettes
Description: In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes and menthol cigarettes
Description: In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
Study: NCT00070200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT04327843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement
Description: Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Decanoate
Description: Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
Study: NCT02972788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Proteins Derivative
Description: Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
Study: NCT03039803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine closure during cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine closure during cesarean section
Study: NCT04828590

Intervention type: OTHER
Intervention: No intervention
Description: Due to observational study
Study: NCT02446145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.
Study: NCT03177044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural treatment
Description: 2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
Study: NCT01814839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTRSC (revusiran)
Description: Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
Study: NCT00070200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin